Addiction Medicine Certification Treatment Planning & Protocols 2

Question 1

A patient with opioid use disorder declines buprenorphine but agrees to extended-release naltrexone. Which prerequisite must be met before initiating XR-naltrexone?

Accepted Answer

Complete 7–10 days of opioid abstinence to avoid precipitated withdrawal

Answer

XR-naltrexone requires full opioid detoxification (typically 7–10 days abstinence) to prevent precipitated withdrawal.

Question 2

Which ASAM level of care is most appropriate for a patient who requires medically managed intensive inpatient services due to severe withdrawal and co-occurring psychiatric instability?

Accepted Answer

Level 4.0 — Medically Managed Intensive Inpatient

Answer

ASAM Level 4.0 provides 24-hour physician-managed care for patients with severe medical and psychiatric instability.

Question 3

Under the ASAM multidimensional assessment, Dimension 3 specifically evaluates which aspect of a patient's presentation?

Accepted Answer

Emotional, behavioral, and cognitive conditions

Answer

ASAM Dimension 3 assesses emotional, behavioral, and cognitive conditions or complications that may affect treatment.

Question 4

A patient with alcohol use disorder has a CIWA-Ar score of 18. Which treatment approach is most clinically appropriate?

Accepted Answer

Initiate symptom-triggered benzodiazepine therapy in a medically supervised setting

Answer

A CIWA-Ar score of 15–20 indicates moderate-to-severe withdrawal requiring symptom-triggered benzodiazepines in a supervised setting.

Question 5

Which of the following best describes the role of contingency management in addiction treatment planning?

Accepted Answer

Using tangible rewards to reinforce drug-negative urine screens and treatment attendance

Answer

Contingency management uses positive reinforcement — typically vouchers or prizes — to reward abstinence and prosocial behaviors.

Addiction Medicine Certification Practice Test

Addiction Medicine Certification Practice Test

Addiction Medicine Certification Treatment Planning & Protocols 2